How does Vesugen differ from conventional cardiovascular peptides?

Unlike larger peptides that work through cell-surface receptors, Vesugen is a short tripeptide proposed to penetrate cell nuclei and regulate gene expression epigenetically. It targets vascular endothelial cells specifically, modulating genes involved in proliferation (Ki-67), inflammation (endothelin-1, E-selectin), and cellular repair (sirtuin-1).

Is Vesugen the same as Ventfort?

No. Ventfort is the natural peptide complex extracted from animal vascular tissue (a Cytomax), while Vesugen is its synthetic counterpart (a Cytogen). Ventfort contains a broader mix of peptides; Vesugen is a single defined tripeptide sequence (KED).

Is Vesugen FDA-approved?

No. Vesugen is not FDA-approved and is not used in mainstream Western medicine. Clinical data comes primarily from Russian research institutions associated with the Khavinson bioregulator program.

Vesugen

A synthetic tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, studied for vascular protection, endothelial function, and age-related cardiovascular decline.

PreliminaryLimited Data

What is Vesugen?

Vesugen is a synthetic tripeptide consisting of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp, or KED), developed by Vladimir Khavinson as part of his bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in vascular tissue. Originally derived from animal aorta, Vesugen targets vascular endothelial cells and has been studied in Russian clinical settings for atherosclerosis, peripheral vascular disease, and age-related cardiovascular decline. With 27 indexed PubMed publications, it is one of the better-studied Khavinson bioregulators.

Why People Talk About It

Vascular protection and atherosclerosis support

Preliminary

Endothelial function restoration in aging

Preliminary

Vasculogenic erectile dysfunction

Preliminary

Neuroprotection and cognitive support in elderly

Preliminary

Anti-aging and biological age reduction

Preliminary

How It Works

Vesugen is a small three-amino-acid peptide that targets blood vessel cells. It is proposed to enter cell nuclei and turn on genes that keep blood vessels healthy — particularly genes involved in cell renewal and reducing inflammation. As we age, these vascular maintenance genes can become silenced, and Vesugen may help reactivate them.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated in available studiesNo significant adverse effects reported across clinical studiesMild injection site reactions possible (injectable form)

Cautions

• Not FDA-approved
• Clinical data is primarily from Russian research
• Quality and purity vary by source
• Should be used under clinician guidance

What We Don't Know

Western clinical trial data is absent. A 32-patient study found no chromatin condensation changes, suggesting nuclear safety, but long-term effects of chronic use have not been evaluated in controlled Western studies.

Published Research

10 studies

Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.

PreclinicalPMID: 39518916

Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease.

ReviewPMID: 34173097

Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis.

PreclinicalPMID: 28539025

Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro.

PreclinicalPMID: 27259496

Effect of Synthetic Peptides on Aging of Patients with Chronic Polymorbidity and Organic Brain Syndrome.

Clinical TrialPMID: 26390612

Molecular aspects of anti-atherosclerotic effects of short peptides.

PreclinicalPMID: 25408528

The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people.

Clinical TrialPMID: 25051774

Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging.

PreclinicalPMID: 25051766

Peptides tissue-specifically stimulate cell differentiation during their aging.

PreclinicalPMID: 22808515

Investigation of antihypoxic properties of short peptides.

PreclinicalPMID: 18546825

Mechanism of Action

Vesugen (Lys-Glu-Asp) is proposed to penetrate cell membranes and interact directly with DNA and histone proteins in vascular endothelial cells. Research demonstrates several molecular targets: it normalizes endothelin-1 expression (elevated in atherosclerosis), restores connexin-mediated cell-cell communication, and enhances sirtuin-1 expression involved in DNA repair. It stimulates Ki-67 proliferation marker expression while reducing p53 and E-selectin (an adhesion molecule involved in atherosclerotic plaque formation). In aging cell cultures, Vesugen specifically induces differentiation factors CXCL12, Hoxa3, and WEGC1, with effects more pronounced in late-passage (aged) cultures. Molecular docking studies show it contacts the MKI67 gene promoter at positions -14 to +12 relative to the transcription start site, supporting an epigenetic mechanism of action. It also modulates expression of senescence markers (p16, p21) and neurogenesis-related genes (nestin, GAP43) in neural tissue.

Evidence Snapshot

Overall Confidence30%

Human Clinical Evidence

Limited but present. A clinical study of 41 men with vasculogenic erectile dysfunction showed significant improvement in penile arterial blood flow after Vesugen treatment (PMID: 25051774). A study of 32 patients with chronic polymorbidity showed significant anti-aging effects and enhanced CNS function with Vesugen, outperforming pinealon (PMID: 26390612). Oral KED improved memory and attention in elderly patients with CNS disorders (PMID: 34173097). No Western clinical trials are indexed.

Animal / Preclinical

Moderate. Vesugen demonstrated antihypoxic properties in animal models (PMID: 18546825). In vitro studies show it normalizes endothelin-1 in atherosclerotic conditions, restores connexin activity, and enhances sirtuin-1 expression in vascular endothelial cells (PMID: 28539025). It stimulates tissue-specific cell differentiation markers in aging cultures, with stronger effects in older cells (PMID: 22808515). Molecular docking confirms interaction with the Ki-67 gene promoter (PMID: 25051766).

Mechanistic Rationale

Moderate-to-strong within the Khavinson framework. Multiple in vitro studies demonstrate specific molecular targets: endothelin-1 normalization, E-selectin reduction, sirtuin-1 enhancement, and Ki-67 upregulation. The epigenetic mechanism through direct DNA interaction is supported by molecular docking data, though independent replication outside the Khavinson group is limited.

Forms & Administration

Vesugen is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. Injectable protocols use 10-20 mg per week subcutaneously. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Use Cases & Evidence Levels

Vascular protection and atherosclerosis support

Preliminary30%

Endothelial function restoration in aging

Preliminary30%

Vasculogenic erectile dysfunction

Preliminary30%

Neuroprotection and cognitive support in elderly

Preliminary30%

Anti-aging and biological age reduction

Preliminary30%

Safety Profile

Safety Information

Common Side Effects

Generally well-tolerated in available studiesNo significant adverse effects reported across clinical studiesMild injection site reactions possible (injectable form)

Cautions

• Not FDA-approved
• Clinical data is primarily from Russian research
• Quality and purity vary by source
• Should be used under clinician guidance

What We Don't Know

Published Research

10 studies

Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.

PreclinicalPMID: 39518916

Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease.

ReviewPMID: 34173097

Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis.

PreclinicalPMID: 28539025

Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro.

PreclinicalPMID: 27259496

Effect of Synthetic Peptides on Aging of Patients with Chronic Polymorbidity and Organic Brain Syndrome.

Clinical TrialPMID: 26390612

Molecular aspects of anti-atherosclerotic effects of short peptides.

PreclinicalPMID: 25408528

The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people.

Clinical TrialPMID: 25051774

Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging.

PreclinicalPMID: 25051766

Peptides tissue-specifically stimulate cell differentiation during their aging.

PreclinicalPMID: 22808515

Investigation of antihypoxic properties of short peptides.

PreclinicalPMID: 18546825

All references link directly to PubMed. Citations are selected by clinicians for relevance and quality.

Related Peptides

Epithalon

Preliminary

A synthetic tetrapeptide studied for its potential to activate telomerase and influence cellular aging.

Thymalin

Moderate

A thymic peptide complex studied for immune system restoration, particularly in aging populations and immunocompromised states.

Pinealon

PreliminaryBeginner

A short tripeptide studied for neuroprotective and cognitive-enhancing properties, part of the Khavinson peptide bioregulator family.

Cortagen

Preliminary

A synthetic peptide bioregulator targeting brain cortex function, studied for cognitive enhancement and neuroprotection in aging.

Vesilute

Preliminary

A synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson system, studied for bladder function support, urinary health, and age-related urogenital decline.

Quick Facts

Class: Bioregulator Peptide
Evidence: Preliminary
Safety: Limited Data
Updated: Apr 2026
Citations: 10PubMed

Also known as

KED TripeptideLys-Glu-AspVascular BioregulatorVezugen

Evidence Score

Overall Confidence30%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.